Roquefort Therapeutics PLC Appointment of Broker

RNS Number : 1220T

Roquefort Therapeutics PLC

20 June 2024

 

20 June 2024

 

Roquefort Therapeutics plc

("Roquefort Therapeutics")

Appointment of Broker

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its broker with immediate effect.

-ENDS-

Enquiries:

Roquefort Therapeutics plc	[phone]
Stephen West (Chairman) / Ajan Reginald (CEO)
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre	[phone]
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	[phone]
Peak IR (Investor Relations) Seb Wykeham	[phone]

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.

 

Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines.  The highly complementary profile of five best-in-class medicines consists of:

·   Midkine antibodies with significant in vivo efficacy and toxicology studies;

·   Midkine RNA therapeutics with novel anti-cancer gene editing action;

·   Midkine mRNA therapeutics with novel anti-cancer approach;

·   STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and

·   MK cell therapy with direct and NK-mediated anti-cancer action

 

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

APPUKUNRSWUNAAR